The Genetics of Glaucoma in Individuals of Caucasian and African Ancestry
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
March 01, 2021 - February 28, 2026
Grant ID
G2019357
Goals
Large studies have identified many genes and genetic variants that increase risk of glaucoma, but little is known about the mechanism. The work described in this proposal will examine the levels of these genes in individual cells in the retina, and how genetic variants change those levels. It will provide the basic information that will enable us to understand mechanism, and may lead to the development of new treatments for glaucoma. Importantly, this work will follow up new findings in African Americans, a group that is disproportionately affected by glaucoma.
Summary
I am collecting additional information about the genetic variants that increase risk of glaucoma. In Aim 1, I will isolate single cells from the human retina–the part of the eye that contains cells that are affected by glaucoma. I will use a new technology that can record all of the cells types in which each individual gene is active, as well as how much of that gene product is made in each cell. One of the main ways that genes increase risk of glaucoma is by changing just how much gene product is made. In Aim 2, I will look at all of the genetic variants that are present in each person whose eyes are examined. I will then be able to see how these genetic variants change the activity of each gene. Many investigators have done this type of analysis in the past, but it always required the entire retina for a single measurement. The new technology that I am using can do the same thing on a single cell, which provides much more useful information. The information that I collect through this work will tell us much more about the ways that glaucoma risk genes work–precisely which cells contain these active genes, and how genetic variants change their activity. This information can tell us much about the root causes of glaucoma which will greatly benefit the development of new drugs and treatments for glaucoma.
Unique and Innovative
Glaucoma is asymptomatic until vision loss has occurred. The low number of ophthalmologists in Nigeria (1 per million people) means that many individuals only seek treatment once their glaucoma has already caused vision loss. Photos of the back of the eye can be taken by a nurse or other individuals, and the subsequent image analysis can highlight possible glaucoma cases without ANY involvement of an ophthalmologist. In this way, a larger number of individuals could be screened, improving early detection of glaucoma while vision loss can be prevented. This same approach could be applied to any low-resource environment.
Foreseeable Benefits
Glaucoma in African ancestry individuals has a more aggressive course and different genetics than in other ancestry groups. Our results may reveal new ways to diagnose glaucoma in African Americans and other African ancestry groups
Related Grants
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
W. Daniel Stamer, PhD
Current Organization
Duke University
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
W. Daniel Stamer, PhD
Current Organization
Duke University
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute